{"name":"Cytori Therapeutics","slug":"cytori-therapeutics","ticker":"","exchange":"","domain":"","description":"Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5213000,"revenueGrowth":-10.5,"grossMargin":0,"rdSpend":8379000,"netIncome":-22386000,"cash":16325000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPSXIwNlY4QXpwM1pSTThkajRZenBRWVFPMkVhYW45TkNVX2F3bUlFRFkyQmNTaHpPYy1xdlZTWXk2bHlJNkdNY3ZtR0hzb0NDbzFfMzBlRG5fUnhVSkxYU2lvNFpXM0FIWDNKWk9xWW1wR19qTFJUZExFOXZrdTVHbnVzNC1EemlkWnE2WXl0b0tnS1d5bjRsSWR3cVh4cnZ2Q2dRVVo3SXNLMC11dmJzWjRDeG1GY0FHdGtFNVVTcFNKZ09uNDVZWDl3RlVqdk5lSVJiSkdfbUY3bUUxQlJZLVhQaXZ2dzZLTzFWaXZwbkpCM2U4OThFU1JMSElnWE1ZTnc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | ","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxObVlxc3U4MFpkUTZaMmVVWTFRVmV0dkxWei1lUF9qdTJNMGpIaTREdFJQTlZzWVBTMFJBRlF5YXpWX1k2ak5NT2J3elIwLUMtOFUtZGF1ZzFmYVIyaWd2Z3pmMzdTb1FqSjhZemdLaUlnRVQxMlRta0cyMGI0Uko5c2pwWEdUQ1ZzV1BZ0gGQAUFVX3lxTE02UWVvN05VYTI4cjVKWTlCMEtjR2hIX2IyQ1NtVTlVOTV0WTdSMzhFUDM1YnM5VDlMM2N6d052R2tPTWRvVWVXZVQ3Vk5kY05KbVNDNkZtamV3ckw3eDhmQWVKWjVHZXZDNWJMMEUwTGR5QVJJRTc5ckc0R05wNm00TWVHc3F4cm1kMmhxdmIweg?oc=5","date":"2024-11-12","type":"pipeline","source":"BioInformant","summary":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies? - BioInformant","headline":"Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5vRUdGWlpkVUliUjVoRzhyVkQ4aF9XRHZzVGUxRl9oX2hoUzdpVVJvNWVLTWRGT2Rsak9yNU94TVZEOWlITGpSeDZpcGJZdGZpOS1qTzFnRkF2QjN3SUZUdkxjWi1fd1RwWkRIOG1Nbw?oc=5","date":"2024-01-20","type":"pipeline","source":"Straits Research","summary":"Thyroid Cancer Drugs Market Size to Jump at US$4.3 billion by 2033 - Straits Research","headline":"Thyroid Cancer Drugs Market Size to Jump at US$4.3 billion by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBYQmViNkNseVprZkdTY0tJNjNYc290Zmd1cGJBSlFVQ3dTZ2wxZ1RjYlNINzhGMlVfNktnSHR2REpsODV2Y2ZWUkw5VFREVjlyMTVrMVpVTFBLcFprYXJsbmhFdEdnYVVKSkE?oc=5","date":"2018-07-10","type":"pipeline","source":"statnews.com","summary":"Brett Kavanaugh, Trump's pick for court, has left trail of opinions on health care and pharma issues - statnews.com","headline":"Brett Kavanaugh, Trump's pick for court, has left trail of opinions on health care and pharma issues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQaUViWmxXVTBERWl1bjZfTmYwUGR3NU4xb0s4S0dGTTI2T09qcGtYSXVLYWF0WmkwczJpUHZEQWxhdjhhWnVkSTBCTXJQTFk1MEQzeUt2Yk5aT3RJWFM1eUJWMlFrYS1LR3doSWpibmFZeEE5N1lYT3p1dllnZEpXR0hYLUtKUmUzUzNHOUtoSXcyOUk?oc=5","date":"2017-06-01","type":"pipeline","source":"Drug Delivery Business","summary":"Cytori launches next-gen Celution cell therapy tech - Drug Delivery Business","headline":"Cytori launches next-gen Celution cell therapy tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9seG1WU2FOaGxBaFhQMDNEM0pfdGtON3MzUXVJNk9feEVvZGQ1UFNpN2NoR0VHUkR2cHgyNFplNzhWbnIxa3JuZ0FBSU1FT05PRFZ5X2FrS3E4YWt4ckxJZG9Qc2JrQ05IYV9FcUZPODhsbzZYZnJEOERR?oc=5","date":"2015-01-26","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"26 Companies at Risk for Delisting - Genetic Engineering and Biotechnology News","headline":"26 Companies at Risk for Delisting","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5213000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":5213000,"period":"2025-12-31"},{"value":5824000,"period":"2024-12-31"},{"value":5824000,"period":"2024-12-31"},{"value":4913000,"period":"2023-12-31"},{"value":2689000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8379000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22386000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":16325000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}